Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 11:05pm CET
   By Debbie Cai 
 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at debbie.cai@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SCICLONE PHARMACEUTICALS,
02/09 SCICLONE PHARMACEUTICALS : Healthcare Stocks Under Scanner -- Aerie Pharma, GW P..
02/09 SCICLONE PHARMACEUTICALS : To Present At BIO CEO & Investor Conference On Februa..
02/01 SCICLONE PHARMACEUTICALS : To Present At BIO CEO & Investor Conference On Februa..
01/08 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Departure of Directors..
01/06 SCICLONE PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8..
2016 SCICLONE PHARMACEUTICALS : Confirms Receipt Of Unsolicited Proposal From GL Capi..
2016 SCICLONE PHARMACEUTICALS : Reports Third Quarter 2016 Financial Results
2016 SCICLONE PHARMACEUTICALS : Research Reports Initiation on Drug Makers Stocks -- ..
2016 SCICLONE PHARMACEUTICALS : Confirms Receipt Of Unsolicited Proposal From GL Capi..
2016 SCICLONE PHARMACEUTICALS : posts 3Q profit
More news
Sector news : Pharmaceuticals - NEC
03:32a Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/20DJBAYER : Trump Backing for Bayer's Monsanto Deal Buoys Investors
02/20DJBAYER : 4Q 2016 -- Forecast
02/20DJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/02 SCICLONE PHARMACEUTICALS : Beyond The Death Of A Sales Process
2016 Adds and drops from the Nasdaq Biotech Index
2016 WEEK IN REVIEW : Week's China Life Science Deals Total $795 Million
2016 SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2016 Results - Ea..
2016 SciClone Pharmaceuticals reports Q3 results
Advertisement
Chart SCICLONE PHARMACEUTICALS,
Duration : Period :
SciClone Pharmaceuticals,  Technical Analysis Chart | SCLN | US80862K1043 | 4-Traders
Full-screen chart
Technical analysis trends SCICLONE PHARMACE...
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Managers
NameTitle
Friedhelm Blobel President, Chief Executive Officer & Director
Jon Sheldon Saxe Chairman
Wai-Shun Wilson Cheung Chief Financial Officer, Secretary & SVP-Finance
Rick J. Hawkins Independent Director
Gregg Anthony Lapointe Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SCICLONE PHARMACEUTICA..-9.72%498
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results